Sanofi upbeat on GLP-1 diabetes drug data; Emergent wins $186M contract; Novartis smoker's cough therapy beats GSK's;

@FierceBiotech: Crucell eagerly accepts $2.3B buyout offer from J&J. Article | Follow @FierceBiotech

 @JohnCFierce: Transition's Tony Cruz gambles and fails on diabetes program, collaborating with Lilly. TT-223 bites the dust. Article | Follow @JohnCFierce

> Sanofi-Aventis says that its GLP-1 Type 2 diabetes drug, lixisenatide, significantly improved glycemic control in a late-stage trial. Sanofi has ambitious plans to expand its presence in the fast-growing diabetes drug market. Story

> Emergent BioSolutions inked a $186.6 million contract with the Department of Health and Human Services to develop a new anthrax vaccine. The five-year contract starts with a $51 million base in the first two years. News

> Novartis reports that its smoker's cough therapy, Onbrez Breezhaler, which is up for U.S. approval, proved more effective than one of GSK's treatments in a late-stage study. Report

> Eddingpharm, a specialty pharmaceutical marketing company focused on the China market, closed on a $24 million Series B financing co-led by OrbiMed Advisors Caduceus Asia Partners Fund and Domain Associates. Eddingpharm release

> Chronix Biomedical, a biomarkers company, today announced that it has completed a Series E financing that raised $1.8 million from existing and new investors. Chronix release

And Finally... Scientists say they found the ‘Homer Simpson' gene. Release

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.